Trends in Anti‐Hyperglycemic Medicines Among US Adults With Diabetes and a History of Stroke
Brain and Behavior · 2026-11 · 16 (11)
DOI: 10.1002/brb3.71921 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, online erschienen am 10.11.2026. Verfasst von Yaojie Cai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing Key Laboratory of Precision Assessment and Intelligent Pre…. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Stroke, Diabetes Mellitus. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Zhejiang Provincial Health Industry Science and Technology Program.
Themen: Diabetes mellitus, Schlaganfall
Abstract (Originalsprache)
Background
Diabetes among adults with a history of stroke is associated with increased risks of recurrent vascular events and disability and greater healthcare costs. Contemporary glucose‐lowering strategies now prioritize individualized therapy based on cardiovascular, renal, and metabolic factors over glycemic targets alone. However, national evidence on patterns of glucose‐lowering medication use for this dual‐diagnosis population is limited.
Methods
We analyzed serial cross‐sectional MEPS data from 2017 to 2023 to characterize glucose‐lowering medication use among US civilian, noninstitutionalized adults aged ≥ 18 years with self‐reported diabetes and a history of stroke. Medication classes were defined via Multum codes and standardized names. Weighted prevalence with 95% CIs and linear trends were estimated. Medication use was compared between adults with and without a history of stroke using base models adjusted for sociodemographic factors and expanded models additionally adjusted for coronary disease history, annual recorded chronic kidney disease, heart failure, obesity, and approximate diabetes duration. Additional analyses used an alternative ICD‐based case definition requiring E11 and I63 records within the same survey year.
Results
Among 2241 person‐years (representing 3.05 million annually), 82.4% used any glucose‐lowering agent. Metformin (52.2%), insulin (35.6%), sulfonylureas (23.1%), GLP‐1RAs (10.5%), DPP‐4is (10.5%), and SGLT2is (9.4%) were most common. GLP‐1RA/SGLT2i use rose from 8.7% to 33.8% (OR per year, 1.36; p < 0.001), whereas the downward trend in DPP‐4i use was not statistically significant (OR per year, 0.91; 95% CI, 0.83–1.01; p = 0.074). In the base models, stroke history was associated with higher odds of insulin use (OR, 1.57) and lower odds of metformin use (OR, 0.78). After additional clinical adjustment, these associations were attenuated (ORs, 1.26 and 0.86, respectively), and neither met the exploratory multiplicity‐adjusted threshold. The alternative ICD‐based cohort included 125 person‐years; trend estimates were imprecise, and some adjusted associations differed from those in the primary analysis.
Conclusions
Adoption of newer agents increased markedly, yet most stroke survivors with diabetes still did not receive GLP‐1RAs or SGLT2is by 2023. The metformin and insulin associations were attenuated after additional clinical adjustment, and neither met the exploratory multiplicity‐adjusted significance threshold. Medication‐use patterns among adults with diabetes and a history of stroke warrant further investigation using data that capture clinical characteristics and treatment timing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing Key Laboratory of Precision Assessment and Intelligent Prevention and Treatment of Cerebrovascular Diseases, Zhuji, China.
- Department of Gastroenterology, Beijing Hospital, National Center For Gerontology; National Clinical Research Center For Gerontology; The Key Laboratory of Geriatrics of NHC; Institute of Geriatric Medicine, Chinese Aca…
- Shaoxing University Medical College, Shaoxing, China.
Förderung
- Zhejiang Provincial Health Industry Science and Technology Program
Zitieren
APA
Cai, Y., Xiong, Y. J., & Lv, T. (2026). Trends in Anti‐Hyperglycemic Medicines Among US Adults With Diabetes and a History of Stroke. Brain and Behavior, 16(11). https://doi.org/10.1002/brb3.71921
Vancouver
Cai Y, Xiong YJ, Lv T. Trends in Anti‐Hyperglycemic Medicines Among US Adults With Diabetes and a History of Stroke. Brain and Behavior. 2026;16(11). doi:10.1002/brb3.71921
BibTeX
@article{Cai2026,
author = {Cai, Yaojie and Xiong, Yu-Jun and Lv, Tian},
title = {Trends in Anti‐Hyperglycemic Medicines Among US Adults With Diabetes and a History of Stroke},
journal = {Brain and Behavior},
year = {2026},
volume = {16},
number = {11},
doi = {10.1002/brb3.71921}
}
EUVIMED